Tag: DNA repair inhibitor therapy

Home / DNA repair inhibitor therapy

Categories

Talazoparib with enzalutamide is approved by FDA for HRR gene-mutated metastatic castration-resistant prostate cancer

July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant p...
dna-repair-inhibitor-therapy

We Are Online! Chat With Us!
Scan the code